<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816539</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A03054-35</org_study_id>
    <nct_id>NCT04816539</nct_id>
  </id_info>
  <brief_title>Comparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function</brief_title>
  <acronym>DECURAR-EMG</acronym>
  <official_title>Comparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function : a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the values of train-of-four ratios with the TetraGraph and thoses obtained with the&#xD;
      TOFscan during recovery of neuromusculat function in surgical patients who have been&#xD;
      administred rocuronium.&#xD;
&#xD;
      Primary outcome : value of TOFratio with the TetraGraph when TOFratio of TOFscan is greater&#xD;
      than or equal to 90% Pilot study : no hypothesis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Train-of-four ratios</measure>
    <time_frame>baseline (J0)</time_frame>
    <description>Value of TOFratio with TetraGraph when TOFratio with TOFscan is greater than or equal to 90% (first value of three greater than or equal to 90%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Train-of-four ratios</measure>
    <time_frame>baseline (J0)</time_frame>
    <description>Value of TOFratio with TetraGraph when TOFratio with TOFscan is greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and eventually 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Train-of-four ratios</measure>
    <time_frame>baseline (J0)</time_frame>
    <description>Value of TOFratio with TOFscan when TOFratio with TetraGraph is greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and eventually 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Train-of-four count</measure>
    <time_frame>baseline (J0)</time_frame>
    <description>Time to recover one, two, three and four responses from TOFcount with TOFscan and TetraGraph</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TetraGraph</intervention_name>
    <description>Use of two monitoring devices of neuromuscular function during surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing an electrive surgical procedure with non emergency and that requires&#xD;
        use of Rocuronium, and willing to participate and provide an informed consent&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age greater than or equal to 18 years old&#xD;
&#xD;
          -  patients willing to participate and provide an informed consent&#xD;
&#xD;
          -  elective surgical procedures, without emergency, administration of rocuronium for&#xD;
             neuromuscular blockade, and recovery of complete neuromuscular function at the end of&#xD;
             the surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with unilateral disorders, such as stroke, carpal tunnel syndrome, broken&#xD;
             wrist with nerve damage, Dupuytren contracture, or similar wrist injury&#xD;
&#xD;
          -  patients with systemic neuromuscular diseases such as myasthenia gravis&#xD;
&#xD;
          -  renal insufficiency or renal failure&#xD;
&#xD;
          -  significant liver disease&#xD;
&#xD;
          -  patients having surgery that would involve prepping the arm into the sterile field&#xD;
&#xD;
          -  allergy to rocuronium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Meistelman</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claude Meistelman</last_name>
    <phone>0383153464</phone>
    <email>c.meistelman@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Claude Meistelman</last_name>
      <phone>0383153464</phone>
      <email>c.meistelman@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

